Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXON 19 DELETION
(
ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/981
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/133
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Afatinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24439929
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Afatinib | Sensitivity | true |